Anemia, Healthy Controls, Iron-deficiency Anemia
Conditions
Brief summary
This is an observational trial, in patients with moderate to severe anemia and control subjects. The main purpose of this study is to understand whether normal brain blood flow, oxygen extraction reserve, white matter volumes, and brain functional connectivity are affected by acquired anemia. The investigators will perform baseline MRI monitoring for all subjects. All eligible subjects will be asked to provide informed consent before participating in the study.
Detailed description
This is an observational trial, in patients with moderate to severe anemia and control subjects. The main purpose of this study is to understand whether normal brain blood flow, oxygen extraction reserve, white matter volumes, and brain functional connectivity are affected by acquired anemia. The investigators will perform baseline MRI monitoring for all subjects. All eligible subjects will be asked to provide informed consent before participating in the study. Comprehensive cerebrovascular MRI, baseline bloodwork, and neurocognitive testing will be collected from all subjects.
Interventions
None listed
Sponsors
Children's Hospital Los Angeles
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
(observational component): * Age between 16 and 60 years of age. * Any ethnicity. * Either sex. * Anemic group: hemoglobin less than 10.5 g/dl on screening hemoglobin. * Control group: hemoglobin \>13.2 g/dl for females, \>14.6 g/dl for males, comparable age, sex and ethnicity to currently enrolled anemic subjects.
Exclusion criteria
(observational component): * Diabetes requiring medication. * Hypertension requiring medication. * Sleep disordered breathing requiring intervention. * Body mass index \>35 (morbid obesity) * Contraindications to MRI, including pacemaker, severe claustrophobia, pregnancy. * Known systemic inflammatory disease such as inflammatory bowel disease, systemic lupus erythematosus, or scleroderma. * Known HIV. Inclusion criteria (interventional component): * Criteria for observational component, plus * ron deficiency anemia based upon attending hematologist interpretation of transferrin saturation, ferritin, and other ancillary labs including hs-CRP, MMA.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Impact of acquired anemia on cerebrovascular oxygen delivery (ml O2/100g/min) | Day 0 | Impact of acquired anemia on cerebrovascular oxygen delivery will be assessed by measuring cerebral blood flow and oxygen content through MRI. |
| Impact of acquired anemia on cerebrovascular flow reactivity (%SI change/%ETCO2) | Day 0 | baseline MRI with blood oxygenation level dependent (BOLD) acquisition will be assessed in response to carbon dioxide exposure to determine whether acquired anemia affects cerebrovascular reserve |
| Impact of acquired anemia on blood brain barrier permeability surface area product (ml H20/100g/min) | Day 0 | baseline PSA product using water-extraction-with-phase-contrast-arterial-spin-tagging (WEPCAST) MRI will be assessed to determine whether acquired anemia affects blood brain barrier permeability to water |
| Impact of acquired anemia on cerebral metabolic rate of oxygen (ml O2/100g/min) | Day 0 | T2 relaxation under spin tagging (TRUST) acquisition via MRI will be used to assess any impact of anemia on cerebral metabolic rate of oxygen. |
| Impact of acquired anemia on total brain blood flow (ml blood/100g/min) | Day 0 | Phase contrast MRI will be assessed to determine whether acquired anemia affects total brain blood flow |
Countries
United States
Outcome results
None listed